Clifutinib

Clifutinib
Clinical data
Other names	HEC-73543
Identifiers
	IUPAC name 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-[4-(3-morpholin-4-ylpropoxy)phenyl]ethynyl]phenyl]urea;
CAS Number	1862226-99-0;
PubChem CID	118665873;
IUPHAR/BPS	13919;
UNII	3BHA83P7NZ;
ChEMBL	ChEMBL6159776;
Chemical and physical data
Formula	C29H34N4O4
Molar mass	502.615 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C#CC3=CC=C(C=C3)OCCCN4CCOCC4;
	InChI InChI=InChI=1S/C29H34N4O4/c1-29(2,3)26-21-27(32-37-26)31-28(34)30-24-11-7-22(8-12-24)5-6-23-9-13-25(14-10-23)36-18-4-15-33-16-19-35-20-17-33/h7-14,21H,4,15-20H2,1-3H3,(H2,30,31,32,34); Key:DWZXYPARIPYQKS-UHFFFAOYSA-N;

Clifutinib is an investigational new drug that is being developed by Sunshine Lake Pharma Co., Ltd. for the treatment of acute myeloid leukaemia (AML). It is a fms related receptor tyrosine kinase 3 (FLT3) inhibitor.^[1]^[2]

References

↑ "Clifutinib besylate". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ Liu B, Kang N, Yang F, Zhang W, Yan X, Wang H, et al. (April 2025). "Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD⁺ Acute Myeloid Leukemia". Journal of Medicinal Chemistry. 68 (8): 7955–7972. doi:10.1021/acs.jmedchem.4c03023. PMID 40213868.